Main Content start here
Main Layout
Report Description

Report Description

India gabapentin market is expected to grow at a steady rate during the forecast period. Gabapentin is an anticonvulsant medication and was initially developed as a novel anti-epileptic for treating numerous types of seizures. The India gabapentin market is driven by the certain advantages of this drug over other anti-epileptics such as a wide therapeutic index, among others. Moreover, Gabapentin is widely used to treat epilepsy which is forecasted to positively influence the market growth. Ongoing research and developmental activities by key market players is further expected to boost the growth of India gabapentin market through FY2026.

The India gabapentin market is segmented based on source, form, strength, distribution channel, application, end user, company, and region. Based on application, the market can be segmented into epilepsy, neuropathic pain, restless legs syndrome, seizures, others. Among these, neuropathic pain segment is expected to witness high growth in the market over the coming years on account of high growth in the number of population having chronic progressive nerve diseases. Also, the efficient use of this drug for the treatment of neuropathic pain is expected to drive this segmental growth in the years to come.

The major players operating in the India gabapentin market are Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Hetero Drugs Ltd., Silverline Chemicals Ltd., Taj Pharmaceuticals Ltd., Divis Laboratories Ltd., Unnati Pharmaceuticals Pvt. Ltd., and others. Major companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive Go-to- Market strategies include mergers & acquisitions, research collaborations and new product developments to expand their geographic reach and to increase their customer basis.

Years considered for this report:

Historical Years: FY2016-FY2019

Base Year: FY2020

Estimated Year: FY2021

Forecast Period: FY2022–FY2026

Objective of the Study:

  • To analyze and estimate the market size of India gabapentin market from FY2016 to FY2019.
  • To estimate and forecast the market size of India gabapentin market from FY2020 to FY2026 and growth rate until FY2026.
  • To classify and forecast India gabapentin market based on source, form, strength, distribution channel, application, end user, company, and regional distribution.
  • To identify dominant region or segment in the India gabapentin market.
  • To identify drivers and challenges for India gabapentin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India gabapentin market.
  • To identify and analyze the profile of leading players operating in India gabapentin market.
  • To identify key sustainable strategies adopted by market players in India gabapentin market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of India gabapentin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Gabapentin manufacturers/ suppliers/ distributors
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to gabapentin

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India gabapentin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • India Gabapentin Market, By Source:
    • In-house
    • Contract Manufacturing Organizations
  • India Gabapentin Market, By Form:
    • Tablet
    • Capsule
    • Others
  • India Gabapentin Market, By Strength:
    • 100 mg
    • 200 mg
    • 300 mg
    • 400 mg
    • Others
  • India Gabapentin Market, By Distribution Channel:
    • Online
    • Offline
  • India Gabapentin Market, By Application:
    • Epilepsy
    • Neuropathic Pain
    • Restless Legs Syndrome (RLS)
    • Seizures
    • Others
  • India Gabapentin Market, By End User:
    • Adult
    • Paediatric
  • India Gabapentin Market, By Region:
    • North
    • South
    • East
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India gabapentin market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
India gabapentin market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  
Table of content

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Gabapentin Market

4.    Executive Summary

5.    Manufacturing Gabapentin

5.1.  Raw Material

5.2.  Machinery

5.3.  Manufacturing Methods

5.4.  Contact Details of Machinery & Raw Material Suppliers

6.    Pharmacodynamic Overview of Gabapentin

6.1.  Mechanism of Action

6.2.  Absorption

6.3.  Volume of Distribution

6.4.  Protein Binding

6.5.  Metabolism

6.6.  Route of Elimination

6.7.  Half-Life

6.8.  Clearance

6.9.  Toxicity

7.    India Gabapentin Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Source (In-house v/s Contract Manufacturing Organizations)

7.2.2.     By Form (Tablet, Capsule, Others)

7.2.3.     By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others)

7.2.4.     By Distribution Channel (Online v/s Offline)

7.2.5.     By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others)

7.2.6.     By End User (Adult v/s Paediatric)

7.2.7.     By Region (North, East, South, West)

7.2.8.     By Company

7.3.  Product Market Map

8.    Market Dynamics

8.1.  Drivers/Opportunities

8.2.  Challenges/Restraints

9.    Market Trends & Developments

10.  Policy & Regulatory Landscape

10.1.              Custom Duty & Taxes

10.2.              Government Subsidy & Benefits

10.3.              Relevant Policies & Regulations (GMP, USFDA, WHO Certifications)

11.  Import & Export Analysis

12.  Pricing Analysis

13.  India Economic Profile

14.  Competitive Landscape

14.1.              Company Profiles

14.1.1.  Aurobindo Pharma Ltd.

14.1.1.1.      Company Brief

14.1.1.2.      Production Plants & Capacity (If Available)

14.1.1.3.      Financials (If Available)

14.1.1.4.      Captive Consumption Vs Merchant Sale

14.1.1.5.      Current & Future Plans

14.1.2.  Glenmark Pharmaceuticals Ltd.

14.1.3.  Sun Pharmaceuticals Industries Ltd.

14.1.4.  Alkem Laboratories Ltd.

14.1.5.  Intas Pharmaceuticals Ltd.

14.1.6.  Hetero Drugs Ltd.

14.1.7.  Silverline Chemicals Ltd.

14.1.8.  Taj Pharmaceuticals Ltd.

14.1.9.  Divis Laboratories Ltd.

14.1.10.                Unnati Pharmaceuticals Pvt. Ltd.

15.  Strategic Recommendations

About Us & Disclaimer

Figures and Tables

Frequently asked questions

Frequently asked questions

Related Reports